Premium
Clozapine and risperidone: combination/ augmentation treatment of refractory schizophrenia: a preliminary observation
Author(s) -
Raskin S.,
Katz G.,
Zislin Z.,
Knobler H. Y.,
Durst R.
Publication year - 2000
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1034/j.1600-0447.2000.101004334.x
Subject(s) - risperidone , clozapine , refractory (planetary science) , schizophrenia (object oriented programming) , psychiatry , medicine , atypical antipsychotic , psychology , dopamine antagonist , antipsychotic , haloperidol , physics , astrobiology , dopamine
Raskin S, Katz G, Zislin Z, Knobler HY, Durst R. Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation. Acta Psychiatr Scand 2000: 101: 334–336. © Munksgaard 2000. Objective: Clozapine and risperidone were the first two antipsychotic drugs of a new class of agents for the pharmacotherapy of schizophrenia. It has been suggested that refractory schizophrenic patients who fail to respond to neither clozapine nor risperidone may respond to a combination/augmentation strategy of both medicaments. Method: Three cases of individuals with unremittent schizophrenia treated via this combination are presented. Response was evaluated by clinical follow‐up and PANSS rating scale. Results: Good clinical results with no noticeable adverse side effects, ascertained by a reduction from baseline scores of the Positive and Negative Syndrome Scale (PANSS) were obtained in all three patients. Conclusion: The findings from this pilot study suggest this combination as a possible therapeutic approach for treating resistant schizophrenic patients.